Generic Rx Delays Could Result From House Medicare Provisions, GPhA Says
Executive Summary
A provision on the "antibundling" of generic drug applications in the House Medicare prescription drug bill could be misused by the brand name industry to delay the market entry of generics, the Generic Pharmaceutical Association says
You may also be interested in...
Generic Rx Reforms: No Automatic “Controversy” For Declaratory Judgments
The Medicare conference bill's Waxman/Hatch reform provisions would require federal courts to determine whether declaratory judgment actions brought by ANDA filers against innovators are a "case or controversy" under the Constitution
Generic Rx Reforms: No Automatic “Controversy” For Declaratory Judgments
The Medicare conference bill's Waxman/Hatch reform provisions would require federal courts to determine whether declaratory judgment actions brought by ANDA filers against innovators are a "case or controversy" under the Constitution
Medicare Bill Retains ANDA “Antibundling” Language “Livable” To GPhA
Medicare prescription drug benefit legislation is likely to contain a modified version of the House bill's "antibundling" provision for generic drug applications following a Sept. 30 Capitol Hill meeting between the brand and generic drug industries